The role of drug-eluting balloon catheters in the treatment of coronary in-stent restenosis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F18%3AE0107685" target="_blank" >RIV/00843989:_____/18:E0107685 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
The role of drug-eluting balloon catheters in the treatment of coronary in-stent restenosis
Original language description
Coronary stent implantation has significantly improved percutaneous coronary interventions and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5-10%. Evidence from controlled clinical studies has suggested that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. In contrast to the DES, the DEB allows short-term passage of the active substance into the vascular wall, preventing hyperproliferation of vascular smooth muscle cells, however, due to the short duration of the effect, DEB do not affect endothelial progenitor cells and stent neoendothelialization so much. Here, we discuss some recent randomized studies that compared different DEB with DES use to treat BMS-ISR or DES-ISR, and the long-term clinical results of those studies.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)